Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
3260
Trial Sponsor
Trial Collaborator
Clinical Trial Start Date
February 15, 2015
0Primary Completion Date
September 21, 2018
0Study Completion Date
February 25, 2020
0Clinical Trial Study Type
Observational0
Intervention Type
Other0
Intervention Name
Observation of suPAR plasma and salivary levels0
Observational Clinical Trial Type
Case-Control0
Observational Study Perspective
Cross-Sectional0
Participating Facility
Official Name
Evaluation of Plasma and Salivary suPAR in Periodontitis and CVD Patients0
Last Updated
April 7, 2020
0Study summary
soluble urokinase-type plasminogen activator receptor (suPAR) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease (CVD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum suPAR levels.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
